The purpose of this report was to evaluate efficacy and safety of second-line therapy with everolimus, an mTOR inhibitor, for the treatment of advanced or metastasised renal cell carcinoma (RCC). A placebo controlled phase III study showed improved progression free survival and acceptable side-effects for the intervention group.
Nevertheless, with the availability of a number of new drugs for the treatment of RCC, the remaining challenge is the determination of the best sequence or combination of these therapies.